Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer: a Multicenter, Retrospective Study

NCT05572645 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05572645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05572645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer: a Multicenter, Retrospective Study
Lead sponsor
Fudan University
Phase
Observational
Overall status
Completed
Start date
October 1, 2022
Completion date
September 1, 2023
Enrollment
333 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer